Objective: On the day of birth, the bleeding time of very low birth-weight (VLBW, <1500 g) neonates is generally prolonged, compared with term neonates. However, their bleeding time generally improves (shortens) over the next 7 to 10 days. Ampicillin can prolong the bleeding times of term and late preterm neonates, but its effect on VLBW neonates, who already have a somewhat prolonged bleeding time initially, is not known.
Introduction
Bleeding times of healthy term neonates are not longer than those of healthy adults. 1, 2 In contrast, very low birth-weight (VLBW, <1500 g) neonates often have subnormal platelet function, and bleeding times that are prolonged, inversely proportionate to their gestational age. [3] [4] [5] However, over the first 7 to 10 days following birth, the bleeding times of VLBW neonates generally improve (shorten) to about that of term neonates. 3, 4 It is not clear whether ampicillin, which can impair platelet function in adults [6] [7] [8] and in term and late preterm neonates, 5 further lengthens the already prolonged bleeding times of VLBW neonates.
This study was designed to test the effect of ampicillin on platelet function of VLBW neonates over their first week following birth. We measured platelet function in two ways, template bleeding time [1] [2] [3] [4] [5] and PFA-100 time. [9] [10] [11] [12] [13] As was the case in our previous study of ampicillin dosing to late preterm and term neonates, 5 we hypothesized that a few doses of ampicillin would have little effect on platelet function, but that ampicillin treatment for the entire first week would prolong the bleeding time.
Methods
Patients in the neonatal intensive care unit (NICU) of the McKayDee Hospital Center, Ogden, UT, USA, were deemed eligible to participate in this study if their birth weight was <1500 g, and if the attending neonatologist ordered intravenous ampicillin treatment on admission to the NICU. A patient with a platelet count <100 000 ml À1 on the first day was considered ineligible. A cranial ultrasound examination, specifically evaluating for intracranial hemorrhage, was not required before study entry, but was obtained at 7 days ( ± 1) after birth as part of routine clinical care in this NICU.
The platelet count, mean platelet volume and hematocrit were measured electronically (Coulter LH 750 Hematology Analyzer, Beckman Coulter, Fullerton, CA, USA). A template bleeding time was performed (by MJS or RDC) using methods previously described. 3, 5, 9 The Intermountain Healthcare Clinical Hematology Laboratory performed the PFA-100 using the manufacture's recommendations (Dade Schering, Miami, FL, USA). Samples for PFA were drawn from a central line (UAC or UVC) when available, otherwise by venipuncture. As we previously reported, we slightly modified the PFA-100 method in order to reduce the amount of blood needed. 5, 9 Specifically, only the epinephrine cartridge (not the adenosine diphosphate cartridge) was used. To maintain the recommended ratio of blood to citrate (9:1), 90 ml of citrate was removed from each blood collection tube (BD Diagnostics, Franklin Lakes, NJ, USA) using a micropipetter (Finnpipettte, Thermo Fisher Scientific, Waltham, MA, USA). This permitted the test sample to be 0.9 ml rather than 1.8 ml. As two PFA-100 tests were performed on each subject, eliminating the adenosine diphosphate cartridge resulted in 1.8 ml less blood than would otherwise be drawn.
Ampicillin was always administered intravenously using a 12-h dosing interval. The number of days ampicillin was administered, and the unit dose administered, were determined by the attending neonatologist, not dictated by the study design. Descriptive statistics were calculated using Graphpad Software (LaJolla, CA, USA). Means and standard deviations were used to express values in groups that were normally distributed, otherwise medians and ranges were used. A paired t-test was used to assess differences in values in each study subject. Statistical significance was set as P<0.05. The Institutional Review Board of the Intermountain Healthcare approved the study protocol, and parents of the participants signed an informed consent document.
Results
During the 10 months the study was open for enrollment (September 2009 to June 2010) 452 patients were admitted to the NICU, of which 59 weighed less than 1500 g at birth. A total of 50 of these were treated with intravenous ampicillin beginning on the first day after birth. Of these, two were ineligible for this study on the basis of a platelet count <100 000 ml À1 . From the remaining 48, parents of 23 were contacted by the research staff and given study information. Parents of the other 25 potentially eligible VLBW neonates were not contacted on the basis of unavailability of an individual (MJS or RDC) to perform the template bleeding time studies. Of the 23 cases where parents were contacted, three declined study participation and the remaining 20 gave written informed consent. All 20 VLBW neonates for whom informed consent was granted were entered into and completed the study protocol.
The 20 neonates, at birth, ranged from 23-to 30-weeks gestation and weighed 500 to 1410 g. Features of these 20 are shown in Table 1 , including their day-1 platelet counts, mean platelet volume measurements, and number with mechanical ventilation. None of the 20 had a positive blood culture, and none had ampicillin dosing continued beyond 15 doses. All were treated with gentamicin, as well as ampicillin. In 18 of the 20, the unit dose of ampicillin was 50 mg per kg of body weight and in the other two it was 100 mg per kg.
All template bleeding times were successful, but six of the 40 attempted PFA-100 tests failed because of microclots in the blood sample. PFA test failure was more common on the repeat specimen (4 of 20) than on the initial specimen (2 of 20).
As shown in Table 2 , the initial (day-1) bleeding times averaged 166 s (95% CI, 138 to 194) and the initial PFA-100 times averaged 119 s (95% CI, 90 to 148). In all, 10 neonates had the ampicillin dosing stopped after four to seven doses. After stopping the ampicillin their bleeding times and PFA-100 times were similar to the initial values. The remaining 10 had their ampicillin dosing continued for 10 to 15 doses. After stopping the ampicillin their bleeding times were on average two minutes longer than the initial values (P ¼ 0.0001 vs initial bleeding time). Moreover, their PFA times trended higher than the initial values by an average prolongation of 44 s (P ¼ 0.07, Table 2 ).
No differences in clinical or laboratory features were identified between those treated with a short course of ampicillin vs those treated with a longer course (Table 3) . Furthermore, we could not find any reasons in the daily progress notes explaining why these 10 had their ampicillin-dosing continued beyond 48 to 72 h. At the conclusion of the ampicillin course, there were no differences in the two groups in platelet count or hemoglobin. A correlation was observed (r ¼ 0.68) between the number of doses of ampicillin given during the first week and the change in bleeding time, from the initial to the final measurement (Figure 1 ).
Discussion
The template bleeding time and the PFA-100 time have been used to assess platelet function of neonates. [1] [2] [3] [4] [5] [9] [10] [11] [12] [13] Other tests of platelet function are less applicable for VLBW neonates, principally because of a larger volume of blood needed. These include light transmittance platelet aggregometry, 14 whole-blood aggregometry, 15 multiple electrode aggregometry, 16 thromboelastography 17 and vasodilator-stimulated phosphoprotein phosphorylation. 18 Ampicillin impairs platelet function and prolongs the bleeding time, 5-8 but it does not do so immediately as occurs with clopidogrel (plavix) or aspirin. 19 Studies in adults, as well as neonates indicate that several doses of ampicillin are needed before platelets become impaired. [5] [6] [7] [8] This lag seems to relate to the time required for ampicillin molecules to intercalate into the platelet membrane lipid bilayer, thereby interfering with receptor binding.
We previously reported that ampicillin can prolong the bleeding time of term and late preterm neonates by an average of 60 s. 5 In this study we extended these observations to VLBW preterm neonates, where this issue might be of greater clinical relevance because of their higher risk of hemorrhagic complications. In our previous study we found base-line bleeding times of 134 s (95% CI 120 to 148) among neonates of 33-to 41-weeks gestation. 5 In our present study of neonates 23-to 30-weeks gestation, In this study we found no prolongation in bleeding time or PFA-100 time after a short course of ampicillin. A short course is typical for NICU patients when the baseline cultures are found to be sterile after 48 to 72 h, because in such patients the likelihood of a bacterial infection is very low. 20 In contrast, those with a 'longer course' of ampicillin had a significant prolongation in bleeding time, averaging two minutes longer than their preampicillin baseline values. This prolongation occurred during the period when the bleeding time of VLBW neonates should be shortening. 3 We recognize that our findings are confounded by the fact that the subjects were not randomly assigned to a short vs a long ampicillin course. We judged that such a design would have ethical problems; thus the ampicillin dosing and duration were always ordered by the responsible neonatologist, independent of this study.
As none of the 20 had a positive culture, we presume those treated with a longer course of ampicillin differed in fundamental ways from those where the ampicillin was stopped after 2 or 3 days. We have no protocol guiding when to stop vs continue antibiotic treatment when cultures are negative, but we assumed those with a longer course had abnormal complete blood count or C-reactive protein findings. In contrast to that speculation we found no differences in CBCs or C-reactive proteins between the two groups to In all, 10 patients had a short course of ampicillin (4 to 7 doses) and 10 had a longer course (10 to 15 doses). All values are in seconds and are expressed as mean and 95% Confidence Intervals. explain the antibiotic treatment duration. We were also unable to find differences in clinical features to explain the differences in antibiotic duration. Perhaps the decision to continue antibiotics beyond 2 or 3 days, when cultures are sterile, is complex and not adequately described by the laboratory and clinical variables we examined. Thus, it can be argued that it is the condition of the neonate resulting in the decision to continue antibiotics, and not the multiple ampicillin doses per se, that is responsible for the prolonged bleeding times. We concede that this is possible, but we submit that biological plausibility and known mechanisms strongly suggest that it is the multiple doses of ampicillin, and not unknown factors, which caused the prolonged bleeding times. We do not know of a way to determine whether a 2-min prolongation in bleeding time produces any clinical risk for a VLBW neonate. Bleeding problems such as intraventricular hemorrhage, bruising, and pulmonary hemorrhage in VLBW neonates are more common during the first week after birth, when the bleeding time is longer, and these are less of a problem in the second week when the bleeding time has normally shortened. 3 We realize this reasoning is indirect and inferential, but we suspect that at the onset of an intraventricular hemorrhage, imposing a 2-min prolongation in bleeding time might result in a larger hemorrhage. Such speculation cannot be validated or dismissed by this study, but drugs that prolong the bleeding time do indeed carry hemorrhagic risks, and such risks are considered when these medications are prescribed. 21, 22 Additional study will be needed in order to know, when a 'longer course' of ampicillin is contemplated in a VLBW neonate, whether prolongation of the bleeding time is indeed a risk to be weighed against potential benefits. Figure 1 Correlation between the doses of ampicillin received in the first week after birth and the change in bleeding time (seconds). The change in bleeding time was calculated by subtracting the bleeding time at the end of the ampicillin course from the bleeding time at the beginning of the ampicillin course.
